Screening of inhibitors for anchorage-independent tumor cell growth from microbial metabolites and their application in cancer chemotherapy
| Project/Area Number |
14560083
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Bioproduction chemistry/Bioorganic chemistry
|
|---|
| Research Institution | Toyama Prefectural University |
|---|
Principal Investigator |
IGARASHI Yasuhiro Toyama Prefectural University, Department of Engineering, Associate Professor, 工学部, 助教授 (20285159)
|
|---|
| Project Period (FY) |
2002 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2003: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 2002: ¥500,000 (Direct Cost: ¥500,000)
|
|---|
| Keywords | antitumor agent / anchorage-independent growth / screening / microbial metabolite / 足場比依存性増殖阻害物質 |
|---|
| Research Abstract |
Inhibitors for anchorage-independent growth of tumor cells were screened from microbial secondary metabolites. Five hundred strains of actinomycetes and one hundred strains of fungi were cultured in liquid medium and the 1-butanol extracts were subjected to the screening. One actinomycete and one fungus showed potent inhibitory activity against the anchorage-independent growth of human colon tumor DLD-1 cells. The active compounds were isolated from the culture broth by chromatography using HPLC analysis and bioassay.
From the actinomycete, a novel antitumor compound TT2149-C was isolated. The producing-strain, was identified as Streptomyces thermoviolaceus TP-A0648 by taxonomic studies. TT2149-C is an analog of spicamycin, which was isolated from Streptomyces sp. as an antitumor antibiotic. TT2149-C inhibited the anchorage-independent growth of DLD-1 cells with the IC_<50> of 29 nM whereas it inhibited the anchorage-dependent growth with. the IC_<50> of 68 nM. TT2149-C showed very pote
… More
nt cytocidal activity against a variety of human cancer cell lines with the IC50 of 0.1 to 120 nM.
A novel antitumor compound anicequol was isolated from the fungus Penicillium aurantiogriseum TP-F0213. The structure of anicequol was confirmed as (3β, 5α, 7β, 11β, 16β-16-acetoxy-3,7,11-trihydroxyergost-22-en-6-one by X-ray diffraction of bis-p-bromobenzoate of anicequol. Anicequol inhibited the anchorage-independent growth of DLD-1 cells with the IC_<50> of 1.2 μM whereas it inhibited the anchorage-dependent growth with the IC_<50> of 40 μM. The selectivity of anicequol is superior to that of TT2149-C. Anicequol did not show activity against protein kinases, farnesyl transferase and tublin function. Structure-activity relationship (SAR) of anicequol, was studied using synthetic derivatives. Acetylation of 3-and 7-hydroxy groups resulted in the loss of activity. However, the acetylation of 3-hydroxy group reduced the toxicity to the anchorage-dependent growth but enhanced the cytotoxicity to the anchorage-independent growth. SAR of anicequol will be studied furthermore. Less
|
Report
(3 results)
Research Products
(2 results)
